This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

ZYNLONTA can be administered in an outpatient setting from the start^1,2

Dose modifications for AEs¹

See SmPC for full information

Find out more

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754.

Abbreviations:
IV: intravenous

References:
1. ZYNLONTA SmPC. 2. Caimi PF et al. Lancet Oncol 2021; 22: 790-800.

PP-30914

Jan, 2026

ZYNLONTA can be administered in an outpatient setting from the start1,2

Dose modifications for AEs1

ZYNLONTA can be administered in an outpatient setting from the start^1,2

Dose modifications for AEs¹